within Pharmacolibrary.Drugs.ATC.N;

model N07AA01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.8333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 2.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00013000000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 8.999999999999999e-05,
    k12             = 0.045,
    k21             = 0.045
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07AA01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Neostigmine is a reversible acetylcholinesterase inhibitor, used primarily in the management of myasthenia gravis, reversal of non-depolarizing neuromuscular blockade after surgery, and treatment of postoperative abdominal distention and urinary retention. It is an approved and widely used medication today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data reported for adult surgical patients receiving intravenous neostigmine for neuromuscular blockade reversal.</p><h4>References</h4><ol><li><p>Berkó, S, et al., &amp; Gáspár, R (2016). Electroporation-delivered transdermal neostigmine in rats: equivalent action to intravenous administration. <i>Drug design, development and therapy</i> 10 1695–1701. DOI:<a href=\"https://doi.org/10.2147/DDDT.S102959\">10.2147/DDDT.S102959</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27274203/\">https://pubmed.ncbi.nlm.nih.gov/27274203</a></p></li><li><p>Hurh, E, et al., &amp; Lee, MG (2000). Effects of neostigmine on the pharmacokinetics of intravenous parathion in rats. <i>Research communications in molecular pathology and pharmacology</i> 108(3-4) 261–273. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11913717/\">https://pubmed.ncbi.nlm.nih.gov/11913717</a></p></li><li><p>Calvey, TN, et al., &amp; Chan, K (1979). Pharmacokinetics and pharmacological effects of neostigmine in man. <i>British journal of clinical pharmacology</i> 7(2) 149–155. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1979.tb00915.x\">10.1111/j.1365-2125.1979.tb00915.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/216382/\">https://pubmed.ncbi.nlm.nih.gov/216382</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07AA01;
